At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial Journal Article
| Authors: | Ganzel, C.; Wang, X. V.; Rowe, J. M.; Richards, S. M.; Buck, G.; Marks, D. I.; Litzow, M. R.; Paietta, E. M.; Foroni, L.; Luger, S. M.; Willman, C. L.; Mullighan, C. G.; Roberts, K. G.; Wiernik, P. H.; Douer, D.; Lazarus, H. M.; Tallman, M. S.; Goldstone, A. H. |
| Article Title: | At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial |
| Abstract: | Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these 757 (43·2%) relapsed; 691 (91·3%) within three years and 66 (8·7%) beyond. Among these 66 patients, median time to relapse was 47 (37–144) months. Relapse beyond three years occurred in 3·8% of all who achieved CR. The cumulative risk of relapse was 40%, 43% and 45% at three, five and ten years respectively. Out of the 1 752 patients who achieved CR, 11·7% underwent autologous and 40·6% allogeneic transplant, while in CR1. Of the autologous patients, 43·2% relapsed early and 3·4% relapsed late. However, among the allogeneic patients, 13·2% relapsed early and only 1·3% late. The five-year overall survival from relapse was 5·8% and 20% in the early and late relapse patients respectively. In conclusion, late relapse in adults with ALL is not uncommon, and is associated with better outcome after relapse compared to early relapse. © 2020 British Society for Haematology and John Wiley & Sons Ltd |
| Keywords: | adult; cancer survival; major clinical study; overall survival; cancer risk; outcome assessment; follow up; cancer incidence; disease association; cohort analysis; retrospective study; acute lymphoblastic leukemia; survival time; leukemia relapse; allotransplantation; leukemia remission; autotransplantation; late relapse; human; male; female; priority journal; article |
| Journal Title: | British Journal of Haematology |
| Volume: | 191 |
| Issue: | 1 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2020-10-01 |
| Start Page: | 37 |
| End Page: | 43 |
| Language: | English |
| DOI: | 10.1111/bjh.16616 |
| PUBMED: | 32220069 |
| PROVIDER: | scopus |
| PMCID: | PMC7687130 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 November 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work